Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition

Journal of the American Society of Nephrology

Volumn 9, Issue 5, 1998, Pages 755-762

  Verhagen, A Marjan G ^a   Rabelink, Ton J ^a   Braam, Branko ^a   Opgenorth, Terry J ^b   Gröne, Hermann Josef ^c   Koomans, Hein A ^a   Joles, Jaap A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG EFFECT; ENZYME INHIBITION; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY ISCHEMIA; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENOVASCULAR HYPERTENSION; VASODILATATION;

EID: 0031959331     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44: 440-444, 1993
2. Benigni A, Zoja C, Corna D, Orisio S, Facchinetti D, Benatti L, Remuzzi G: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27: 416-423, 1996
3. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489, 1995
4. B receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 50: 962-972, 1996
5. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992
6. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
7. Reyes AA, Karl IE, Klahr S: Role of arginine in health and in renal disease. Am J Physiol 267: F331-F346, 1994
8. Chaveau P, Chadefaux B, Coudé JM, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinema, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43[Suppl 41]: S72-S77, 1993
9. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91: 308-318, 1993
10. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993
11. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9: 1136-1142, 1994
12. Erley CM, Rebmann S, Strobel U, Schmidt T, Wehrmann M, Osswald H, Risler T: Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp Nephrol 3: 293-299, 1995
13. Boulanger CM, Lüscher TF: Release of endothelin from the porcine aorta: Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590, 1990
14. Dzau VJ, Gibbons GH, Cooke JP, Omoigui N: Vascular biology and medicine in the 1990s: Scope, concepts, potentials, and perspectives. Circulation 87: 705-719, 1993
15. Rabelink TJ, Kaasjager KAH, Stroes ESG, Koomans HA: Endothelin in renal pathophysiology: From experimental to therapeutic application. Kidney Int 50: 1827-1833, 1996
16. Kohan DE: Endothelins in the normal and diseased kidney. Am J Kidney Dis 29: 2-26, 1997
17. Sventek P, Li J-S, Grove K, Deschepper CF, Schiffrin EL: Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension 27: 49-55, 1996
18. Nakamura T, Ohyama Y, Masuda H, Kurashina T, Saito Y, Kato T, Sumino H, Sato K, Sakamaki T, Sasaki A, Nagai R: Chronic blockade of nitric oxide synthesis increases urinary endothelin-1 excretion. J Hypertens 15: 373-381, 1997
19. ω-nitro-L-arginine methyl ester: Correlation with topography of vascular endothelin-1 gene expression. Hypertension 28: 188-195, 1996
20. A endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation 95: 240-244, 1997
21. G-nitro-L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res 72: 387-395, 1993
22. Ashkenazi A, Ramachandran J, Capon DJ: Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. Nature 340: 146-150, 1989
23. Pinkas-Kramarski R, Stein R, Lindenboim L, Sokolovsky M: Growth factor-like effects mediated by muscarinic receptors in PC12M1 cells. J Neurochem 59: 2158-2166, 1992
24. G-nitro arginine (L-NOARG), a novel L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 99: 408-412, 1990
25. G-nitroarginine in brain in vitro and in vivo. Biochem Biophys Res Commun 176: 1136-1141, 1991
26. G-methylarginine. Biochem Biophys Res Commun 170: 96-103, 1990
27. 5-[imino(nitroamino) methyl]-1-ornithine) impairs endothelium-dependent dilations by inhibiting cytosolic nitric oxide synthesis from 1-arginine. Naunyn-Schmiedeberg's Arch Pharmacol 341: 143-147, 1990
28. A-selective receptor antagonist. J Pharmacol Exp Ther 276: 473-481, 1996
29. Wu-Wong JR, Dixon DB, Chiou WJ, Opgenorth TJ: Endothelin receptor antagonists: Effect of serum albumin on potency and comparison of pharmacological characteristics. J Pharmacol Exp Ther 281: 791-798, 1997
30. Ribeiro MO, Antunes E, Muscara MN, De Nucci G, Zatz R: Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension 26: 150-155, 1995
31. A receptors participate in the hemodynamic and renal effects of chronic nitric oxide blockade? J Cardiovasc Pharmacol 26[Suppl 3]: S462-S465, 1995
32. G-nitro-L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol 28: 142-148, 1996
33. Bouriquet N, Dupont M, Herizi A, Mimran A, Casellas D: Preglomerular sudanophilia in L-NAME hypertensive rats: Involvement of endothelin. Hypertension 27[Part 1]: 382-391, 1996
34. Moreau P, Takase H, Küng CF, Shaw S, Lüscher TF: Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension 29: 763-769, 1997
35. Hocher B, Thöne-Reinecke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer H-H, Schleuning W-D, Theuring F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 1380-1389, 1997
36. - production in human alveolar macrophages. Am J Physiol 261: L478-L484, 1991
37. DeCaterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin S, Liao JK: Nitric oxide decreases cytokine-induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J Clin Invest 96: 60-68, 1995
38. Kurose I, Wolf R, Grisham MB, Aw TY, Specian RD, Granger DN: Microvascular responses to inhibition of nitric oxide production: Role of active oxidants. Circ Res 76: 30-39, 1995
39. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76: 301-314, 1994
40. Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC: Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int 46: 653-665, 1994
41. Stoos BA, Garcia NH. Garvin JL: Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct. J Am Soc Nephrol 6: 89-94, 1995
42. Henderson SA, Lee PH, Aeberhard EE, Adams JW, Ignarro LJ, Murphy WJ, Sherman MP: Nitric oxide reduces early growth response-1 gene expression in rat lung macrophages treated with interferon-gamma and lipopolysaccharide. J Biol Chem 269: 25239-25242, 1994
43. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol 271: C1424-C1437, 1996
44. Yu L, Gengaro PE, Niederberger M, Burke TJ, Schrier RW: Nitric oxide: A mediator in rat tubular hypoxia/reoxygenation injury. Proc Natl Acad Sci USA 91: 1691-1695, 1994
45. Benigni A, Zoja C, Remuzzi G: Biology of disease: The renal toxicity of sustained glomerular protein traffic. Lab Invest 73: 461-468, 1995